Bank of New York Mellon Corp Has $9.62 Million Stock Holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Bank of New York Mellon Corp cut its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 6.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 437,515 shares of the life sciences company's stock after selling 30,447 shares during the period. Bank of New York Mellon Corp owned about 0.57% of Integra LifeSciences worth $9,621,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Quadrant Capital Group LLC lifted its holdings in shares of Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after buying an additional 1,371 shares in the last quarter. Sterling Capital Management LLC grew its holdings in shares of Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after purchasing an additional 1,931 shares during the last quarter. Covestor Ltd boosted its holdings in shares of Integra LifeSciences by 61.8% during the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after buying an additional 2,071 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Integra LifeSciences during the first quarter worth approximately $223,000. Finally, NorthRock Partners LLC purchased a new stake in Integra LifeSciences in the 4th quarter valued at $251,000. 84.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IART has been the subject of a number of analyst reports. JPMorgan Chase & Co. reduced their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. JMP Securities lowered their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Wells Fargo & Company dropped their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Truist Financial cut their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Finally, Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Stock Up 6.0%

IART traded up $0.68 on Tuesday, reaching $12.05. The company's stock had a trading volume of 975,478 shares, compared to its average volume of 973,889. The company has a quick ratio of 0.72, a current ratio of 1.21 and a debt-to-equity ratio of 0.81. Integra LifeSciences Holdings Corporation has a fifty-two week low of $11.06 and a fifty-two week high of $32.49. The stock has a 50 day moving average of $12.70 and a two-hundred day moving average of $18.28. The company has a market capitalization of $936.41 million, a price-to-earnings ratio of -31.71, a P/E/G ratio of 0.62 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The firm had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. During the same period in the previous year, the company earned $0.55 earnings per share. The business's revenue for the quarter was up 3.7% on a year-over-year basis. As a group, analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.